Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Palisade Bio (PALI) Preferred Shares Issued (2022)

Palisade Bio has reported Preferred Shares Issued over the past 1 years, most recently at -$19.9 million for Q4 2022.

Quarterly Preferred Shares Issued changed N/A to -$19.9 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$19.9 million through Dec 2022, changed N/A year-over-year, with the annual reading at $19.9 million for FY2021, N/A changed from the prior year.
Preferred Shares Issued was -$19.9 million for Q4 2022 at Palisade Bio.
Over five years, Preferred Shares Issued peaked at -$19.9 million in Q4 2022 and troughed at -$19.9 million in Q4 2022.